Phone -
Email -
We aim to understand how genetic factors associated with a poor prognosis, such as deletions of IKZF1, dictate tumor cell behavior and drive therapy resistance. Moreover, we use reverse genetic screens to identify pathways that are essential for the resistance phenotype aimed at designing combination therapies that either prevent or cure relapse.